Related references
Note: Only part of the references are listed.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
B Cell Signaling and Fate Decision
Tomohiro Kurosaki et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28 (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.
R. R. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Mary Ellen Conley et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
Maite P. Quiroga et al.
BLOOD (2009)
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
Lisa Pleyer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells
Jonathan M. Irish et al.
BLOOD (2006)
Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma
Murali Gururajan et al.
JOURNAL OF IMMUNOLOGY (2006)
Basal B-cell receptor signaling in B lymphocytes:: mechanisms of regulation and role in positive selection, differentiation, and peripheral survival
EM Fuentes-Pananá et al.
IMMUNOLOGICAL REVIEWS (2004)
Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cγ Src homology 2-Src homology 3 linker
LA Humphries et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Chronic lymphocytic leukemia: revelations from the B-cell receptor
FK Stevenson et al.
BLOOD (2004)
Regulation of B-cell fate by antigen-receptor signals
H Niiro et al.
NATURE REVIEWS IMMUNOLOGY (2002)
Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase
WN Khan
IMMUNOLOGIC RESEARCH (2001)
Share Paper
